These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 20577)

  • 21. Neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. Focus on dopamine (D1, D3, D4) and 5-HT2a receptors.
    Harrison PJ
    Br J Psychiatry Suppl; 1999; (38):12-22. PubMed ID: 10884896
    [No Abstract]   [Full Text] [Related]  

  • 22. Central nervous system dopamine receptors.
    Creese I
    Adv Biochem Psychopharmacol; 1980; 21():235-42. PubMed ID: 6103649
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical evidence for multiple dopamine receptors in man.
    Meltzer HY
    Commun Psychopharmacol; 1979; 3(6):457-70. PubMed ID: 44694
    [No Abstract]   [Full Text] [Related]  

  • 24. [Biochemistry of schizophrenia and mechanism of action of neuroleptics].
    Loo H; Cuche H; Sechter D
    Sem Hop; 1982 Dec; 58(44):2565-72. PubMed ID: 6130604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Antipsychotic drug therapy for patients with behavioral and psychological symptoms of dementia(BPSD)].
    Kudo T
    Seishin Shinkeigaku Zasshi; 2007; 109(7):657-63. PubMed ID: 17969953
    [No Abstract]   [Full Text] [Related]  

  • 26. Changes in cerebral dopamine metabolism and receptors during one-year neuroleptic administration and subsequent withdrawal: relevance to brain biochemistry in schizophrenia.
    Clow A; Jenner P; Theodorou A; Marsden CD
    Adv Biochem Psychopharmacol; 1980; 24():53-5. PubMed ID: 6105799
    [No Abstract]   [Full Text] [Related]  

  • 27. [Diagnosis and treatment of endogenous psychoses (author's transl)].
    Hesse C
    MMW Munch Med Wochenschr; 1980 Dec; 122(50):1803-7. PubMed ID: 6110183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relationship between epilepsy and schizophrenia: a biochemical hypothesis.
    Trimble M
    Biol Psychiatry; 1977 Apr; 12(2):299-304. PubMed ID: 15665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biochemical aspects of schizophrenia.
    Lewis ME
    Essays Neurochem Neuropharmacol; 1980; 4():1-67. PubMed ID: 6104597
    [No Abstract]   [Full Text] [Related]  

  • 30. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
    Pietraszek M
    Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Schizophrenia.
    Morrison PD; Murray RM
    Curr Biol; 2005 Dec; 15(24):R980-4. PubMed ID: 16360673
    [No Abstract]   [Full Text] [Related]  

  • 32. Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence.
    Hornykiewicz O
    Annu Rev Pharmacol Toxicol; 1977; 17():545-59. PubMed ID: 17361
    [No Abstract]   [Full Text] [Related]  

  • 33. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms of action of anti-psychotic drugs.
    Strange PG
    Biochem Soc Trans; 1999 Feb; 27(2):175-8. PubMed ID: 10093729
    [No Abstract]   [Full Text] [Related]  

  • 35. Dopamine and schizophrenia--proof at last?
    Harrison PJ
    Lancet; 2000 Sep; 356(9234):958-9. PubMed ID: 11041394
    [No Abstract]   [Full Text] [Related]  

  • 36. Central dopaminergic mechanisms in schizophrenia.
    Owen F; Crow TJ; Poulter M
    Acta Psychiatr Belg; 1987; 87(5):552-65. PubMed ID: 2897760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Physiopathology of schizophrenia. Some biologic aspects].
    Tissot R
    Schweiz Arch Neurol Neurochir Psychiatr; 1984; 135(1):29-40. PubMed ID: 6148787
    [No Abstract]   [Full Text] [Related]  

  • 38. The development of new drugs for the treatment of schizophrenia.
    Cookson J
    Br J Hosp Med; 1987 Dec; 38(6):542-8. PubMed ID: 2893648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Amines in mental disorders (author's transl)].
    Takahashi R
    Tanpakushitsu Kakusan Koso; 1977; 22(6):815-21. PubMed ID: 337391
    [No Abstract]   [Full Text] [Related]  

  • 40. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.